**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 82769

**Manuscript Type:** REVIEW

**Tissue-specific cancer stem/progenitor cells: Therapeutic implications**

Yehya A *et al*. TSCSC therapy targets and PDO models

Amani Yehya, Joe Youssef, Sana Hachem, Jana Ismael, Wassim Abou-Kheir

**Amani Yehya, Joe Youssef, Sana Hachem, Jana Ismael, Wassim Abou-Kheir,** Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut 1107-2020, Lebanon

**Author contributions:** Yehya A contributed conceptualization, investigation, methodology, visualization, and validation, wrote the original draft, and reviewed and edited the manuscript; Youssef J, Hachem S, and Ismael J contributed investigation, methodology, and validation, wrote the original draft, and reviewed and edited the manuscript; Abou-Kheir W contributed conceptualization, project administration, supervision, validation, and visualization, reviewed and edited the manuscript, and gave final approval; All authors have read and approved the final manuscript.

**Corresponding author: Wassim Abou-Kheir, MSc, PhD, Associate Professor,** Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Bliss Street, Hamra, Beirut 1107-2020, Lebanon. wa12@aub.edu.lb

**Received:** December 28, 2022

**Revised:** February 14, 2023

**Accepted:** April 12, 2023

**Published online:**

**Abstract**

Surgical resection, chemotherapy, and radiation are the standard therapeutic modalities for treating cancer. These approaches are intended to target the more mature and rapidly dividing cancer cells. However, they spare the relatively quiescent and intrinsically resistant cancer stem cells (CSCs) subpopulation residing within the tumor tissue. Thus, a temporary eradication is achieved and the tumor bulk tends to revert supported by CSCs' resistant features. Based on their unique expression profile, the identification, isolation, and selective targeting of CSCs hold great promise for challenging treatment failure and reducing the risk of cancer recurrence. Yet, targeting CSCs is limited mainly by the irrelevance of the utilized cancer models. A new era of targeted and personalized anti-cancer therapies has been developed with cancer patient-derived organoids (PDOs) as a tool for establishing pre-clinical tumor models. Herein, we discuss the updated and presently available tissue-specific CSC markers in five highly occurring solid tumors. Additionally, we highlight the advantage and relevance of the three-dimensional PDOs culture model as a platform for modeling cancer, evaluating the efficacy of CSC-based therapeutics, and predicting drug response in cancer patients.

**Key Words:** Cancer stem cells; Therapy resistance; Tissue-specific cancer stem cell markers; Patient-derived organoids; Pre-clinical cancer models

Yehya A, Youssef J, Hachem S, Ismael J, Abou-Kheir W. Tissue-specific cancer stem/progenitor cells: Therapeutic implications. *World J Stem Cells* 2023; In press

**Core Tip:** Therapeutic approaches targeting cancer stem cell (CSC) markers hold great promise toward developing effective anti-cancer treatment. Tissue-specific CSCs (TSCSCs) possess unique expression profile that allows for their identification, isolation, and targeting. TSCSCs, isolated from patient tumor tissues, were shown to form organ analogs or patient-derived organoids (PDOs) under specific culturing conditions *in vitro.* These models simulate the original tumor characteristics in a three-dimensional culture dish. As such, PDOs have the potential to be used in patient-specific *in vitro* drug clinical trials and proof-of-concept studies on CSC-targeted therapies.

**INTRODUCTION**

Cancer disease remains a leading cause of death worldwide. Despite significant progress directed toward developing anti-cancer therapies, the successful management of cancer remains impeded by multiple challenges, including metastatic dissemination, conventional-therapy resistance, and disease relapse[1,2]. Accumulating evidence suggests that the cancer stem cells (CSCs) subpopulation plays a vigorous role in sustaining the tumorigenic properties, thus contributing to tumor re-growth and progression[3] (Figure 1). This subpopulation of multipotent cells possesses unique properties of self-renewal and differentiation and is capable of extensively proliferating and generating different lineages of cancerous cells, which constitute the tumor bulk and contribute to the heterogeneous phenotype found in tumors[2,4].

CSCs may arise from the transformation of normal stem cells (SCs) found within tissues or from the de-differentiation of differentiated cells[5]. They were first identified in acute myeloid leukemia[6], and compelling evidence later showed that they exist in a variety of solid tumors where they act as key drivers of tumor progression and metastasis[7,8]

CSCs harbor multiple resistance mechanisms that enrich cancer hallmarks and result in the failure of conventional anti-cancer therapies. One underlying mechanism is the disrupted intracellular pathways that profoundly control CSCs behavior. For instance, overexpression of the Notch pathway plays a dual role that is context and cell-type-dependent, acting either as an oncogene or tumor suppressor[9-11]. In the context of CSCs, the Notch pathway has been implicated in proliferation, angiogenesis, metastasis, stemness maintenance, tumor immune evasion, and resistance to radiation[9,11-13]. Moreover, the Wnt pathway has been linked to the activation of dormant CSCs, their proliferation, maintenance, and inhibition of apoptosis. This pathway also plays a role in the metastasis and de-differentiation of CSCs[14,15]. Besides, the Hedgehog pathway is associated with increased proliferation, maintenance, and self-renewal of CSCs, as well as their migration, invasiveness, and resistance to chemotherapy[14,16,17]. Additionally, the NF-κB pathway is implicated in self-renewal, maintenance, and inhibition of apoptosis of CSCs, as well as regulation of epithelial to mesenchymal transition (EMT), angiogenesis, and metastasis[18]. Finally, the aberrant expression of the JAK/STAT3 pathway promotes cell survival and stemness properties, as well as metastasis and resistance to chemotherapy[14,19]. The intrinsic regulation of CSCs also occurs at the level of stemness-related transcription factors (TFs) such as OCT-4, SOX2, KLF4, c-MYC, STAT3, and NANOG, as well as epigenetics and epi-transcriptomics, which contribute to stemness maintenance and plasticity of CSCs[11]. Additionally, CSCs are regulated at an extrinsic level by their microenvironment, specifically by cancer-associated fibroblasts and tumor-associated macrophages. The tumor microenvironment is a major player in modulating CSCs resistance, metastasis, and heterogeneity[11,20].

The resistance mechanisms of CSCs further include their overexpression of DNA repair genes, resulting in resistance to radiotherapy and other DNA-damaging agents[21]. Also, they express upregulated multidrug efflux pumps such as ATP-binding cassette (ABC) transporters that mediate the active transport of chemotherapeutic drugs out of the cell[22]. CSCs were shown as well to overexpress aldehyde dehydrogenases (ALDHs) which are enzymes involved in the detoxification of aldehydes, chemotherapeutic agents, and reactive oxygen species[23]. Another mechanism that promotes the survival of CSCs is their ability to exist at a reversible quiescent state in the G0 phase, which contributes to their drug resistance since most chemotherapeutic agents target highly proliferative tumor cells[24]. Thus, standard therapies succeed at reducing tumor size but tend to spare the highly resistant CSCs subpopulation. The successful elimination of tumors, therefore, necessitates targeting the residual dormant CSCs to yield long-lasting eradication of cancer and prevent relapse.

In this review, we provide a recapitulation of the main tissue-specific CSC (TSCSC) biomarkers in five of the most diagnosed solid tumors. Importantly, we highlight the beneficial role of these CSCs in providing relevant preclinical cancer models and thus improving CSC-targeted therapies.

**Tissue-Specific Cancer Stem Cells**

Given the importance of CSCs in tumor progression and prognosis, several attempts were made to identify and isolate CSCs from the tumor mass based on the markers they express. CSCs express a wide spectrum of markers, some of them being more universal than others. Several markers, mostly located on the cell surface, are often used in combination to ensure a more tissue-specific isolation of targeted CSCs. Here we provide an updated overview of the most prominent TSCSC surface markers, focusing on five solid cancers (prostate, colon, bladder, breast, and lung). Refer to Table 1 for the full list of markers.

***Prostate-specific cancer stem cells***

The presence of prostate CSCs (PCSCs) was identified by Collins *et al*[25] using SCs markers (integrin α2β1 and CD133) that were previously identified in the normal prostate epithelium[25,26]. This subpopulation of PCSCs isolated from human prostate cancer (PC) biopsies showed a high expression of CD44, CD133, and integrin α2β1. The isolated cells exhibited high proliferative ability and were highly invasive on MatrigelTM. Moreover, they possessed a high self-renewal ability and could also differentiate into cells expressing the same phenotype as PC cells, thus re-establishing the original heterogeneous tumor from which they were isolated[27].

CD133(Prominin-1), a cell surface glycoprotein, remains one of the most used biomarkers to identify and isolate PCSCs either alone or in combination with other markers. In fact, CD133+ PC cells that were isolated from human PC cell line exhibited self-renewal ability, which was correlated with their expression of stemness genes[28]. These cells could also generate a heterogeneous tumor mass when transplanted into immunocompromised mice. Moreover, they displayed high clonogenic abilities and led to the formation of tumor spheres (prostaspheres) that were more malignant than the ones formed by CD133- PC cells. Furthermore, the CD133+ cells were chemo-resistant and demonstrated high proliferation[28]. Interestingly, a well-established combination of CD133+ and CD44+ PC cells allowed the isolation of PCSCs and the formation of spheroids characterized by heterogeneous PC cells[29].

CD44 (also referred to as P-Glycoprotein 1) is a transmembrane glycoprotein that interacts with several extracellular matrix components, such as collagen, hyaluronic acid, osteopontin, and matrix metalloproteinases. It is one of the most conventional markers used to identify and isolate PCSCs. The expression of CD44 allowed the isolation of cells that were able to differentiate into all types of PC epithelium leading to complete reconstitution of the original tumor bulk when injected into immunocompromised mice[30]. Notably, CD44+ PC-derived cells expressed elevated levels of several mRNAs associated with stemness[31]. This marker was also associated with several aspects of PC tumorigenesis including proliferation, invasion, adhesion, EMT initiation, metastasis, and therapy resistance[32].

T cell receptor alpha locus (TRA-1-60) is a carbohydrate addition to podocalyxinis, which is a cell surface antigen that belongs to the CD36 family. TRA-1-60 is expressed on pluripotent SCs conferring them the ability to induce differentiation. TRA-1-60 was shown to be overexpressed in PC cells as compared to the adjacent normal prostate tissue, which qualifies it as a favorable marker to specifically target PCSCs while sparing normal cells[33]. Moreover, it was detected in the peripheral blood of patients with metastatic PC[34]. The isolation of TRA-1-60+ cells led to the generation of spheres and initiation of PC in a more efficient manner as compared to other known PCSCs markers. TRA-1-60 was then combined with two other markers of PCSCs (CD166 and CD151) leading to a more enhanced sphere-forming ability. Furthermore, the injection of the triple-marker-positive cells was able to form tumors with at least 5-fold more efficiency as compared to TRA-1-60+ cells alone[35].

CD117 (also termed c-Kit) is a member of the Type-III tyrosine kinase receptors known to be involved in several cancer mechanisms by binding to its stem cell factor (SCF) ligand[36]. CD117 overexpression was detected in PC[37]. A recent study suggested that CD117 may be considered a potential marker for PCSCs because it was shown to display a broad spectrum of tumorigenic abilities[38]. In fact, CD117 stimulated PC cell proliferation and migration. Moreover, CD117+ cells were able to form 1.35-fold larger prostaspheres as compared to CD117- cells. Most importantly, CD117+ cells expressed stemness genes and their implantation into immunocompromised mice led to PC initiation[38].

CD49f (integrin α6 or ITGA6) is a transmembrane glycoprotein that was demonstrated to be a putative marker of PCSCs. CD49fhigh cells were shown to be tumor-initiating cells in the Pten-null PC model[39]. Moreover, CD49f was shown to be the most selective marker for targeting colony-forming cells[40]. Additionally, it was expressed on the surface as well as in the middle of prostatospheres[41]. Importantly, the expression of CD49f allowed the isolation of sphere-forming SCs[42].

In addition to the ones discussed above, there are several markers that can be used to target PCSCs including ALDH1A1 (ALDH 1 family member A1)[43,44], trop-2 (Tumor-associated calcium signal transducer 2)[45], CD166 (activated leukocyte cell adhesion molecule)[46,47], EpCAM (Epithelial cell adhesion molecule)[48], and ABCG2 (ATP binding cassette super-family G member 2)[49].

***Colon-specific cancer stem cells***

Colon CSCs (CCSCs) were first identified and isolated by Ricci-Vitiani *et al*[50] after the injection of colon cancer (CC) CD133+ cells into immunocompromised mice, which led to the generation of the original tumor mass contrary to their CD133- counterparts. The CD133+ cells were able to exponentially grow *in vitro* as undifferentiated spheres while preserving the same phenotypic properties of the initial colon tumor[50]. O'Brien *et al*[51] in 2007 also showed that all CC-initiating cells were CD133+ cells that were able to either maintain themselves as undifferentiated CCSCs or to differentiate and therefore sustain the tumor heterogeneity[51].

Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) (also recognized as FEX; HG38; GPR49; GPR67) is a seven-transmembrane G-protein coupled receptor. LGR5 is an “orphan” receptor abundantly expressed in active SCs of the intestinal crypts[52]. LGR5 was shown to be overexpressed in CC[53]. A growing body of evidence supports the idea that LGR5 is a main marker of CCSCs. For instance, human LGR5+ CC cells were visualized as the CSC pool in proliferating CC tissue[54]. Furthermore, LGR5 was demonstrated to be a marker of tumor-initiating cells, where implantation of LGR5+ cells was able to form colon tumors,indicating that LGR5 provides a dynamic stemness characteristic in CC[55]. Additionally, LGR5 was correlated with tumor proliferation due to the ability of LGR5+ cells to form more multipotent spheres as compared to LGR5- cells[56]. Notably, LGR5 was shown to be involved in the colony formation capacity of CCSCs[56,57]. Importantly, LGR5 was found to have an essential role in CC metastasis where organoids derived from LGR5+ cells led to liver cancer formation in the absence of a primary tumor[55]. In addition, LRG5 was selected to be the most suitable CSC marker that identifies immature cancer cells in regional lymph nodes of CC patients[58].

EpCAM(also known as CD326) is a Type-I transmembrane glycoprotein that serves as an epithelial cell adhesion molecule. Interestingly, EpCAM along with its reprogramming TFs were shown to be overexpressed in CC-initiating cells leading to a high self-renewal ability and increased invasiveness[59]. In fact, EpCAM was considered to be a robust CCSCs marker[60]. Indeed, it was used along with CD133 and CD44 to initiate CC in mice[61]. Furthermore, EpCAM provided more enhanced CSC-like properties when combined with LRG5 and CD44[56]. Moreover, EpCAM was proven to promote CC invasion and metastasis, as EpCAMhigh/CD44+ cells were visible in corresponding liver metastasis regions of CC patients[62].

CD44 was also shown to be a robust marker for CCSCs. In fact, a single CD44+ cell was able not only to generate a sphere, but also to form a tumor with similar characteristics as the primary one from which it was isolated[63]. Moreover, the expression of CD44 was correlated with CC proliferation[4]. Furthermore, CD44 was reported as a stemness marker in spherical clusters[64]. In addition, CD44 was considered a reliable marker for the prediction of hepatic cancer metastasis in CC patients[65].

ALDH1 is also selected as a potential marker for CCSCs. ALDH1expression increased during CC tumorigenesis and the implantation of only 25 ALDH1+ cells into immunocompromised mice led to the generation of xenograft tumors even in the absence of other CCSCs markers such as CD133 and CD44[66]. Furthermore, ALDH1 expression conferred high tumorigenic abilities and chemo-resistance to CC cell lines[67]. Interestingly, ALDH1 was linked to lymph node and vascular invasion in CC patients[68].

Among the most specific CSCs related to CC are LGR5, CD44 and EpCAM. However, the combination of multiple markers allows more accurate detection of CSCs which was proven when LGR5, CD44 and EpCAM resulted in more potent CSCs properties as compared to each marker alone[56]. Other markers are also attributed to CCSCs such as CD59[69], Prox1 a regulator of Notch-independent LGR5+ SCs[70,71], CD24[4,64], CD166[72], and ABCB5 (ATP binding cassette super-family B member 5)[73].

***Bladder-specific cancer stem cells***

Bladder CSCs (BCSCs) were first isolated in 2009 by using markers for normal basal bladder SCs (CD44+). It was found that the CD44+ subpopulation of bladder cancer (BC) cells was 10 to 200 more likely to form tumors in immunocompromised mice in comparison with their CD44‑ counterparts[74]. Additionally, CD44+ BCSCs efficiently maintained the heterogeneity of the initial tumor mass after serial transplantation[74].

Epithelial membrane antigen (EMA, also known as MUC1) is a membrane-bound glycoprotein that belongs to the family of mucins[75]. EMA+ bladder cells are usually located in the mature differentiated layer of the urothelium, whereas EMA- cells are found in the basal layers, where SCs reside. It was demonstrated that EMA- BC cells had a greater colony-forming ability when compared with the unsorted BC population[75,76]. BCSCs can thus be identified through the combination of EMA- and CD44+ BC cells[77].

CD47 (also known as integrin associated protein) is a transmembrane protein overexpressed on the surface of CD44+ BCSCs compared to the CD44- subpopulation and was thus hypothesized to be a BCSCs marker[78,79]. CD47 acts like a “don’t eat me” signal by interacting with the signal regulatory protein-1 receptor on the surface of macrophages and neutrophils. Thus, CD47 has an immunosuppressive role, protecting the BSCSC from phagocytosis[78,79], that makes it a promising target for cancer therapy[80,81].

ALDH1A1has also been used to isolate BCSCs.In fact, ALDH1A1+ cells retained the stem-cell ability to divide asymmetrically, yielding both ALDH1A1+ and ALDH1A1- cells[82]. Additionally, ALDH1A1+ BCSCs exhibited a greater tumorigenic potential both *in vitro* (sphere formation ability) and *in vivo* (xenografts in immunocompromised mice) compared to ALDH1A1- BC cells[82]. Knocking down the ALDH1A1 gene in BCSCs reduced their proliferation, confirming the key role played by the ALDH enzyme in BCSCs division and renewal[83]. Furthermore, ALDH1A1 BCSCs maintained the original tumor heterogeneity after sequential transplantations into immunocompromised mice[83]. Finally, ALDH+ BCSCs demonstrated an enhanced ability to migrate and invade tissues contrary to ALDH- BC cells[82].

67LR+ (67KDa Laminin Receptor)/ CD66c- (also known as CEACAM6) BC cells were demonstrated to have stemness properties. These markers, similar to CD44, are also present in normal bladder SCs[84]. He *et al*[85] showed that 67LR+ BCSCs were 5 to 10 times more potent in initiating tumors *in vivo* compared to 67LR- ones[85]. In addition, 67LR+ BCSCs expressed a panel of genes involved in stemness and resistance to chemotherapy and radiation[85,86]. Similarly, CD66c- cells were demonstrated to be more tumorigenic than the CD66c+ counterparts[85].

CD133+ BC cells were shown to upregulate the expression of genes involved in pluripotency. This subpopulation of BC cells was also more resistant to the chemotherapeutic agent cisplatin and to radiation. Additionally, CD133+ BCSCs exhibited a greater tumorigenicity both *in vitro* and *in vivo*, as well as a more aggressive proliferation in immunocompromised mice in comparison to CD133- BC cells[87].

Additional markers are also used for the identification of BSCSC namely MAGE-A3 (Melanoma antigen family A, 3)[88], BCMab1[79], and several members of the cytokeratin family of proteins (CK5+, CK17+, CK18-, CK20-)[89].

***Breast specific cancer stem cells***

The importance of breast CSCs (BrCSCs) markers was first demonstrated by Al-Hajj *et al*[90] only a subpopulation of human breast cancer (BrC) cells appeared to lead to the formation of tumors in immunocompromised mice. Al-Hajj *et al*[90] isolated ESA+CD44+CD24-/Low cells from human BrC tissue, and showed that as low as 200 of these cells were enough to initiate cancer in immunocompromised mice, whereas more than 50000 BrC cells with a different phenotype were unable to form tumors[90].

CD44 and CD24are often used in combination to detect and isolate BrCSCs[91].In addition to its key role in adhesion, cell survival, metastasis and angiogenesis, CD44 act as a TF to regulate metastasis and stemness of BrCSCs[92,93]. On the other hand, CD24 is a cell surface adhesion glycoprotein which plays a key role in cell-cell and cell-extracellular matrix (ECM) interactions[94,95]. Even though CD24 is overexpressed in a number of cancers (including BrC), only CD44+CD24-/Low BrCSCs were able to form tumors in immunocompromised mice[90]. CD44+CD24-/Low BrCSCs were also shown to be more resistant to chemotherapy[91].

ALDH1has also been used to target BrCSCs, as it was shown that ALDH1+ BrC cells were more resistant to chemotherapy and were able to form tumors in immunocompromised mice in comparison to ALDH1- cells[96]. ALDH1 is essential for the early development of the stemness properties of BrCSCs[97]. Interestingly, the subpopulation of BrC cells expressing ALDH1 is distinct from the CD44+CD24-/Low BrCSCs, with minimal overlap between the two (approximately 1%)[91]. Moreover, ALDH1+/CD44+ BrCSCs were highly tumorigenic, with a higher metastatic potential, and greater resistance to cancer therapies[91].

To date, CD44, CD24 and ALDH1 remain the most used biomarkers to isolate BrCSCs. Although there is little overlap between CD44+CD24-/Lowand ALDH1+ BrCSCs, cells that share all three markers were more tumorigenic[98]. Moreover, the CD44/CD24 markers were more associated with cell proliferation and tumorigenesis while the ALDH1 marker was positively correlated with tumor metastasis[98]. Nonetheless, other markers have been studied and found suitable for the identification of BrCSCs, such as CD133 (in triple negative BrC; TNBC), GD2 (ganglioside in TNBC), CD49f, CD61+ (β3 integrin in Her2 BrC), CD29(β1 integrin), CD90,and EpCAM[99-101].

***Lung cancer stem cell markers***

Lung cancer is histologically divided into non-small cell lung carcinoma cells (NSCLC) and small cell lung carcinoma (SCLC)[102]. Due to a higher incidence and the greater ease to obtain NSCLC tissue, NSCLC CSCs (referred to afterward as lung CSCs; LCSCs) markers have been better characterized.

CD166 (also known as ALCAM) has also been associated with stemness properties of NSCLC. CD166 is a member of the immunoglobulin superfamily of cell adhesion molecules and participates in both homophilic and heterophilic interactions. Additionally, CD166 plays an important role in migration and invasion of LCSCs[103]. CD166 was characterized by Zhang *et al*[104] as the most robust cell marker for isolating LCSCs among other candidates (CD44, EpCAM and CD133)[104]. In contrast to CD166- NSCLC cells which failed to form tumors *in vivo*, CD166+ LCSCs were able to initiate tumors in immunocompromised mice. Furthermore, CD166+ NSCLC cells had enhanced self-renewal properties and were able to consistently form spheres *in vitro*.

The CD133+ subpopulation of NSCLC cells were able to indefinitely divide and form spheres in an *in vitro* setting, whereas CD133- NSCLC cells were characterized by a slow growth and an inability to form spheres[105]. These results also parallel the *in vivo* ability of CD133+ LCSCs to form tumors in immunocompromised mice compared to CD133- cells; the CD133+ xenografts were histologically similar to the initial cancer mass[105,106]. Moreover, the expression of CD133 in LCSCs was associated with increased resistance to chemotherapy and radiation[105,107]. Finally, CD133+ LCSCs are more prone to metastasize than their CD133- counterparts, especially to lymphoid organs. In fact, detection of CD133+ metastatic NSCLC in lymph nodes is indicative of a poor prognosis[107].

CD44has also been studied as a marker to isolate LCSCs. Accordingly, CD44+ NSCLC cells demonstrated a greater ability to form spheres *in vitro* and to initiate tumors in immunocompromised mice in comparison to CD44- cells. Additionally, CD44+ LCSCs upregulated several stemness TFs to maintain their pluripotent properties. CD44+ LCSCs were also more resistant to the chemotherapeutic agent cisplatin compared to CD44- cells[108]. Moreover, the expression of CD44 in LCSCs was associated with an enhanced ability to metastasize and invade tissues[20].

CD90 (also known as Thy-1) is a glycosylphosphatidylinositol-anchored surface protein that is involved in cell-cell as well as cell-ECM interactions[109]. Initial studies have shown that CD90+ NSCLC cells demonstrated greater self-renewal and proliferative properties and expressed a higher level of stemness genes. Additionally, when compared to a control, as few as 5000 CD90+ LCSCs were able to initiate tumors in immunocompromised mice, indicating the stronger tumorigenicity associated with CD90[110].

ALDH1 was also suggested to be a LCSCs marker. Indeed, ALDH1+ LCSCs exhibited enhanced proliferative abilities and self-renewal properties[111,112]. Accordingly, knocking down the ALDH1A3 gene greatly reduced the tumorigenicity and clonogenicity of LCSCs[113]. In addition, ALDH1high LCSCs also showed greater resistance to chemotherapeutic drugs in comparison to ALDH1low cells[112]. Interestingly, the overexpression of the TAZ oncogene induces the formation of LCSCs by activating the ALDH1 gene[114] ALDH1 also appears to play a key role in chemoresistance as its inhibition leads to the re-sensitization of LCSCs to cisplatin[115].

Of note, additional markers have been used to isolate LCSCs. These include but are not limited to CD47, CD87, CD117, EpCAM, and CK5[116,117].

**TSCSCs’ beneficial role in cancer modeling for therapeutic implications**

The conception of CSCs-targeted therapies relies on employing the above-mentioned CSCs' resistant characteristics and markers, which allows for CSCs' isolation, enrichment, characterization, and targeting[118]. CSCs-based therapeutic strategies include selectively targeting the stemness markers, such as the TSCSCs' surface markers, TFs, ABC transporters, and ALDHs[14,119]. As well as, the disrupted signaling pathways that enrich CSCs'-resistant features and contribute to their survival, proliferation, self-renewal, and differentiation. Also, targeting the tumor microenvironment components which acts as a foster niche in protecting CSCs[14,119].

In spite of the significant advances in CSCs' research and the great interest in drug discovery, there are currently few therapeutic approaches that have reached the late clinical stages. Many CSCs-targeting therapeutics performing remarkably *in vitro* and *in vivo* cultures have faced multiple hurdles in clinical trials[14,120]. One major reason behind this is the irrelevance of the preclinical cancer models being used[121-123]. Thus, more relevant CSCs models, that reflect the original tumor behavior of the individual patients, might strengthen the rationale for developing effective CSCs-targeted therapeutic modalities and complement more conventional cancer therapies.

A new era of targeted and personalized anti-cancer therapies has evolved with the three-dimensional (3D) patient-derived organoids (PDOs)[124]. This versatile technique relies on the exclusive ability of SCs to give rise to organ-like structures known as organoids[125]. Sato *et al*[126] established the first organoid model with small intestinal crypt LGR5+ SCs[126]. Subsequently, models of normal and cancer PDOs from multiple tissues were derived successfully[127-134].

The formation of the 3D microscopic organoids from patient tumor tissues is accomplished using specific culturing conditions that are designed to preserve the CSCs component of the patient's tumor[135]. The formed PDOs, hence, recapitulate the structural and functional complexity constituting the originating tumor, mediated by the CSCs’ ability for self-renewal and differentiation into multiple cell types[136,137]. PDOs tool allows the modeling of human carcinogenesis in an *in vitro* culture dish[138,139]. Precisely, the process followed to generate cancer PDOs includes utilizing a tumor tissue sample, surgically isolated from a cancer patient, and dissociating it into single-cell suspension using mechanical dissociation and enzymatic digestion methods. The heterogeneous population of cells obtained, containing TSCSCs, is then cultured in proper culturing conditions to allow the self-organization of cells into functional units or tissue-specific architectures; organ analogs. The suspended culturing system includes the usage of biological or synthetic hydrogel scaffolds that mimic the natural ECM components. In addition to using a specific culturing medium that contains a cocktail of growth factors and inhibitors to imitate the organ stem cell niche, allow the generation of distinct component lineages, and stimulate the long-term expansion of organoids[140,141].

As PDOs are CSCs-based structures and replicate faithfully the heterogeneity and histological characteristics of the original cancers, they gain superiority over other models in terms of mimicking tumor microenvironments, facilitating the formation of ECM, exhibiting adequate proliferation rates with representative cellular morphology, maintaining the expression of ‘stemness-related’ markers and genes, and demonstrating a realistic individualized drug response[142-144]. This nominates PDOs to be ideal preclinical drug-response models for providing perspectives for testing novel CSCs-targeted therapies and evaluating the potential drug effectiveness in cancer patients (Figure 2).

PDOs technique generally shares several main steps but differs in varying degrees depending on the type of tissue being processed. Scaffold-based techniques are mostly adopted in culturing PDOs, where MatrigelTM is commonly used. The latter is a mixture of heterogeneous and gelatinous proteins secreted by mouse sarcoma cells. It comprises mainly adhesive proteins such as laminin, collagen IV, entactin, and heparin sulphate glycoprotein, which resemble the ECM and provide interactive and structural support to the cells[145-148]. Moreover, the universal organoid medium used in the culturing system adopts the first protocol developed by Sato *et al*[126] which includes advanced DMEM/F12 medium supplemented with epidermal growth factor, Noggin (NOG), and Wnt agonist R-spondin-1[126,127]. Other factors were then added including anaplastic lymphoma kinase 3/4/5 inhibitor A83-01, dihydrotestosterone, fibroblast growth factor-10, fibroblast growth factor-2, prostaglandin E2, nicotinamide (NAM), and p38 inhibitor SB202190, N-acetylcysteine (NAC), B27 supplement and Rho kinase inhibitor Y-27632 to culture PDOs successfully[149].

To date, organoids derivation from multiple human tumors including prostate, colon, bladder, breast, and lung cancers has been described, with varying success rates[133, 150-155]. The established PDOs are subjected to tissue-specific genes and lineage markers expression studies to confirm that they represent the original tumor of the patient. Importantly, the cancerous origin of these organoids is confirmed by checking for the CSCs markers specific to each tumor tissue. The patient drug response to the therapy of interest can then be evaluated primarily by assessing the organoids' formation efficiency and size.

For example, a study done by Cheaito *et al*[150] established a minimum of 5-factor medium including NAC, NOG, A83-01, B27, and NAM to grow and maintain PC PDOs. Histopathological, transcriptomic, immunofluorescent, and immunohistochemical studies showed that the formed PDOs mimicked the histological architecture and prostate lineage profiles of their corresponding tissue specimens. This was confirmed by the presence of both prostate epithelial lineages, as the organoids stained positive for the luminal- (CK8, AR, and PSA) and basal- (CK5, CK14, and p63) specific markers. In addition, an intermediate cell population, co-expressing luminal CK8 and basal CK5 markers was also detected. Interestingly, CSCs markers, CD44 and CD49f, positive staining demonstrated the existence of putative stem‑like cells within the bulk of the PDOs. Furthermore, differential drug response, between different patient samples, was recognized upon treatment with chemo-, radio-, and androgen-deprivation therapies[150]. In another study, Monzer *et al*[151] succeeded in establishing and propagating PDOs that model CC disease. The formed organoids recapitulated the architecture and the characteristics of CC tissues as revealed by the co-expression of the epithelial marker lineage CK19 and the CSC surface marker CD44. The organoids derived from different patients showed to exhibit different responses to Diiminoquinone treatment tested alone or in combination with Fluorouracil (5FU) chemotherapeutic drug. Similarly, Al Bitar *et al’s* study[152] showed different responses to individual and combination treatments of radiation and Thymoquinone in CC PDOs.

Moreover, Yu *et al*[153] utilized BC PDOs to evaluate chimeric antigen receptor (CAR)-T cell-mediated cytotoxicity against BC. Analysis was done to confirm that the established organoids recapitulate the heterogeneity and the key features of the parental BCs. Based on a set of luminal (CK20, uroplakin II, and GATA3) and basal markers (CK5, P63, and CD44), the formed organoids were classified into luminal or basal subtypes, respectively. All the BC PDOs and their corresponding tumors expressed Ki67 and E-cadherin, confirming their epithelial origin and high proliferative ability. Additionally, the specific surface antigen profiling of each tumor sample was analyzed, and the MUC1 antigen was shown to be highly expressed among all tested antigens, in both the cancer tissues and their derived organoids. MUC1 was then used as a putative target to test the efficacy of second-generation CAR-T cells in BC PDOs[153]. Furthermore, a promising study done by Chen *et al*[154], showed the significance and applicability of using BrC PDOs as pre-clinical models for broader cancer studies, and more specifically as a tool to provide personalized therapy recommendations for patients with advanced refractory disease. This study focused mainly on deriving PDOs from specimens isolated from patients with advanced clinical features, including drug-resistant and metastatic BrC. The histopathological, immunohistochemical, and genomic characteristics were shown to be well inherited by the formed PDOs from the drug-treated as well as treatment-naïve tumors. Distinctive drug responses were also observed[154]. Furthermore, Kim *et al*[133] demonstrated the distinctive therapeutic responses of LC and normal bronchial PDOs, derived from patient tissues comprising five histological subtypes of LC and non-neoplastic bronchial mucosa. The differential responses to the tested drugs were shown to be affected by the individual genomic alterations profile. The PDOs were also proved to duplicate the tissue architecture and maintain the genomic alterations of the parental lung tumors during long-term expansion *in vitro*[133].

**CONCLUSION**

In this review, we have discussed briefly some of the CSC features that are known to account for cancer resistance and relapse and make CSCs promising anti-cancer targets. Additionally, we have summarized the updated list of the TSCSC molecular markers in prostate, colon, bladder, and lung tumors that are significant to selectively isolate and therapeutically target the CSCs subpopulation. Besides, we highlighted the advantage of utilizing the CSC-based PDO models to simulate carcinogenesis and predict patient-specific drug responses *in vitro.*

Despite the present challenges[156,157], PDOs are highly credible models that possess more physiological and pathological relevance than traditional ones. This robust method proved to faithfully maintain the histological, genetic, and stemness characteristics of their respective native tissues. Interestingly, the CSCs profile mimicked by the PDOs can serve as a platform for testing CSCs-targeted therapeutics. To our knowledge, there are no clinical trials discussing cancer PDOs in a preclinical context for testing CSC-targeted therapeutics[158].

Indeed, PDOs have prospective applications in patient-specific *in vitro* drug clinical trials and proof-of-concept studies on CSC-targeted therapies and -resistance mechanisms. If remarkable advancements are made, cancer patients will ultimately benefit from this radical technology.

**ACKNOWLEDGEMENTS**

We want to thank the members of the Abou-Kheir’s Laboratory (The WAKers).

**REFERENCES**

1 **Sun Y**. Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. *Med Res Rev* 2015; **35**: 408-436 [PMID: 25588753 DOI: 10.1002/med.21338]

2 **Batlle E**, Clevers H. Cancer stem cells revisited. *Nat Med* 2017; **23**: 1124-1134 [PMID: 28985214 DOI: 10.1038/nm.4409]

3 **Chang JC**. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. *Medicine (Baltimore)* 2016; **95**: S20-S25 [PMID: 27611935 DOI: 10.1097/MD.0000000000004766]

4 **Huang JL**, Oshi M, Endo I, Takabe K. Clinical relevance of stem cell surface markers CD133, CD24, and CD44 in colorectal cancer. *Am J Cancer Res* 2021; **11**: 5141-5154 [PMID: 34765317]

5 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

6 **Lapidot T**, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994; **367**: 645-648 [PMID: 7509044 DOI: 10.1038/367645a0]

7 **Hermann PC**, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell* 2007; **1**: 313-323 [PMID: 18371365 DOI: 10.1016/j.stem.2007.06.002]

8 **Charafe-Jauffret E**, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clin Cancer Res* 2010; **16**: 45-55 [PMID: 20028757 DOI: 10.1158/1078-0432.CCR-09-1630]

9 **Wang J**, Sullenger BA, Rich JN. Notch signaling in cancer stem cells. *Adv Exp Med Biol* 2012; **727**: 174-185 [PMID: 22399347 DOI: 10.1007/978-1-4614-0899-4\_13]

10 **Rampias T**, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. *Nat Med* 2014; **20**: 1199-1205 [PMID: 25194568 DOI: 10.1038/nm.3678]

11 **Naz F**, Shi M, Sajid S, Yang Z, Yu C. Cancer stem cells: a major culprit of intra-tumor heterogeneity. *Am J Cancer Res* 2021; **11**: 5782-5811 [PMID: 35018226]

12 **Venkatesh V**, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, Kaginelli SB, Kuppanna G, Kallappa CG, Basalingappa KM. Targeting Notch signalling pathway of cancer stem cells. *Stem Cell Investig* 2018; **5**: 5 [PMID: 29682512 DOI: 10.21037/sci.2018.02.02]

13 **Clara JA**, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. *Nat Rev Clin Oncol* 2020; **17**: 204-232 [PMID: 31792354 DOI: 10.1038/s41571-019-0293-2]

14 **Yang L**, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, Cui H. Targeting cancer stem cell pathways for cancer therapy. *Signal Transduct Target Ther* 2020; **5**: 8 [PMID: 32296030 DOI: 10.1038/s41392-020-0110-5]

15 **Su YJ**, Chang YW, Lin WH, Liang CL, Lee JL. An aberrant nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-elicited promotion of the cancer stem cell phenotype. *Oncogenesis* 2015; **4**: e157 [PMID: 26075748 DOI: 10.1038/oncsis.2015.17]

16 **Sari IN**, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY. Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells. *Cells* 2018; **7** [PMID: 30423843 DOI: 10.3390/cells7110208]

17 **Usui T**, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, Hazama S, Takenouchi H, Nakajima M, Tsunedomi R, Suzuki N, Nagano H, Sato K, Kaneda M, Sasaki K. Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. *Int J Mol Sci* 2018; **19** [PMID: 29642386 DOI: 10.3390/ijms19041098]

18 **Kaltschmidt C**, Banz-Jansen C, Benhidjeb T, Beshay M, Förster C, Greiner J, Hamelmann E, Jorch N, Mertzlufft F, Pfitzenmaier J, Simon M, Schulte Am Esch J, Vordemvenne T, Wähnert D, Weissinger F, Wilkens L, Kaltschmidt B. A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells. *Cancers (Basel)* 2019; **11** [PMID: 31083587 DOI: 10.3390/cancers11050655]

19 **Wang T**, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, Somlo G, Jandial R, Ann D, Hanash S, Jove R, Yu H. JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. *Cell Metab* 2018; **27**: 136-150.e5 [PMID: 29249690 DOI: 10.1016/j.cmet.2017.11.001]

20 **Heng WS**, Gosens R, Kruyt FAE. Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting. *Biochem Pharmacol* 2019; **160**: 121-133 [PMID: 30557553 DOI: 10.1016/j.bcp.2018.12.010]

21 **Desai A**, Webb B, Gerson SL. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. *Radiother Oncol* 2014; **110**: 538-545 [PMID: 24440048 DOI: 10.1016/j.radonc.2013.10.040]

22 **McIntosh K**, Balch C, Tiwari AK. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. *Expert Opin Drug Metab Toxicol* 2016; **12**: 633-644 [PMID: 27116192 DOI: 10.1080/17425255.2016.1179280]

23 **Vasiliou V**, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. *Hum Genomics* 2005; **2**: 138-143 [PMID: 16004729 DOI: 10.1186/1479-7364-2-2-138]

24 **Chen J**, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* 2012; **488**: 522-526 [PMID: 22854781 DOI: 10.1038/nature11287]

25 **Collins AT**, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. *J Cell Sci* 2001; **114**: 3865-3872 [PMID: 11719553 DOI: 10.1242/jcs.114.21.3865]

26 **Richardson GD**, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. *J Cell Sci* 2004; **117**: 3539-3545 [PMID: 15226377 DOI: 10.1242/jcs.01222]

27 **Collins AT**, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res* 2005; **65**: 10946-10951 [PMID: 16322242 DOI: 10.1158/0008-5472.CAN-05-2018]

28 **Kanwal R**, Shukla S, Walker E, Gupta S. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. *Cancer Lett* 2018; **430**: 25-33 [PMID: 29775627 DOI: 10.1016/j.canlet.2018.05.014]

29 **Acikgoz E**, Soner BC, Ozdil B, Guven M. CD133+/CD44+ prostate cancer stem cells exhibit embryo-like behavior patterns. *Acta Histochem* 2021; **123**: 151743 [PMID: 34157581 DOI: 10.1016/j.acthis.2021.151743]

30 **Gu G**, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor *in vivo*. *Cancer Res* 2007; **67**: 4807-4815 [PMID: 17510410 DOI: 10.1158/0008-5472.CAN-06-4608]

31 **Patrawala L**, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. *Oncogene* 2006; **25**: 1696-1708 [PMID: 16449977 DOI: 10.1038/sj.onc.1209327]

32 **Ni J**, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, Kearsley JH, Li Y. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. *Prostate* 2014; **74**: 602-617 [PMID: 24615685 DOI: 10.1002/pros.22775]

33 **Heath EI**, Heilbrun LK, Smith D, Schopperle WM, Ju Y, Bolton S, Ahmed Q, Sakr WA. Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer. *Anticancer Res* 2018; **38**: 6361-6366 [PMID: 30396958 DOI: 10.21873/anticanres.12994]

34 **Schäfer C**, Ju Y, Tak Y, Vazquez C, Han SJ, Tan E, Shay JW, Holmqvist M, Danuser G, Schopperle WM, Bubley G. TRA-1-60-positive/CD45(low) cells found in the peripheral blood of prostate cancer patients with metastatic disease - A proof-of-concept study. *Heliyon* 2020; **6**: e03263 [PMID: 32021935 DOI: 10.1016/j.heliyon.2020.e03263]

35 **Rajasekhar VK**, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. *Nat Commun* 2011; **2**: 162 [PMID: 21245843 DOI: 10.1038/ncomms1159]

36 **Wiesner C**, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thüroff JW, Vessella RL, Cher ML, Bonfil RD. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. *Neoplasia* 2008; **10**: 996-1003 [PMID: 18714401 DOI: 10.1593/neo.08618]

37 **Kerr BA**, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, Klink JC, Mir MC, Sturey T, Hansel DE, Heston WD, Stephenson AJ, Klein EA, Byzova TV. CD117⁺ cells in the circulation are predictive of advanced prostate cancer. *Oncotarget* 2015; **6**: 1889-1897 [PMID: 25595903 DOI: 10.18632/oncotarget.2796]

38 **Harris KS**, Shi L, Foster BM, Mobley ME, Elliott PL, Song CJ, Watabe K, Langefeld CD, Kerr BA. CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance. *Sci Rep* 2021; **11**: 1465 [PMID: 33446896 DOI: 10.1038/s41598-021-81126-6]

39 **Mulholland DJ**, Xin L, Morim A, Lawson D, Witte O, Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. *Cancer Res* 2009; **69**: 8555-8562 [PMID: 19887604 DOI: 10.1158/0008-5472.CAN-08-4673]

40 **Yamamoto H**, Masters JR, Dasgupta P, Chandra A, Popert R, Freeman A, Ahmed A. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. *PLoS One* 2012; **7**: e46979 [PMID: 23071686 DOI: 10.1371/journal.pone.0046979]

41 **Bahmad HF**, Cheaito K, Chalhoub RM, Hadadeh O, Monzer A, Ballout F, El-Hajj A, Mukherji D, Liu YN, Daoud G, Abou-Kheir W. Sphere-Formation Assay: Three-Dimensional *in vitro* Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells. *Front Oncol* 2018; **8**: 347 [PMID: 30211124 DOI: 10.3389/fonc.2018.00347]

42 **Goldstein AS**, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. *Proc Natl Acad Sci U S A* 2008; **105**: 20882-20887 [PMID: 19088204 DOI: 10.1073/pnas.0811411106]

43 **Matsika A**, Srinivasan B, Day C, Mader SA, Kiernan DM, Broomfield A, Fu J, Hooper JD, Kench JG, Samaratunga H. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. *Pathology* 2015; **47**: 622-628 [PMID: 26517640 DOI: 10.1097/PAT.0000000000000325]

44 **Gorodetska I,** Offermann A, Püschel J, Lukiyanchuk1 V, Gaete G, Kurzyukova A, Schwarz1 F, Lange T, Knopf F, Wielockx B, Krause1 M, Perner S, Dubrovska1 A. The distinct role of ALDH1A1 and ALDH1A3 in the regulation of prostate cancer metastases. *BioRxiv* 2021 [DOI: 10.1101/2021.05.08.443223]

45 **Trerotola M**, Rathore S, Goel HL, Li J, Alberti S, Piantelli M, Adams D, Jiang Z, Languino LR. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. *Am J Transl Res* 2010; **2**: 135-144 [PMID: 20407603]

46 **Jiao J**, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. *PLoS One* 2012; **7**: e42564 [PMID: 22880034 DOI: 10.1371/journal.pone.0042564]

47 **Hansen AG**, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone. *Cancer Res* 2014; **74**: 1404-1415 [PMID: 24385212 DOI: 10.1158/0008-5472.CAN-13-1296]

48 **Ni J**, Cozzi P, Hao J, Beretov J, Chang L, Duan W, Shigdar S, Delprado W, Graham P, Bucci J, Kearsley J, Li Y. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. *Int J Biochem Cell Biol* 2013; **45**: 2736-2748 [PMID: 24076216 DOI: 10.1016/j.biocel.2013.09.008]

49 **Wang L**, Stadlbauer B, Lyu C, Buchner A, Pohla H. Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1. *Am J Cancer Res* 2020; **10**: 3784-3800 [PMID: 33294267]

50 **Ricci-Vitiani L**, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. *Nature* 2007; **445**: 111-115 [PMID: 17122771 DOI: 10.1038/nature05384]

51 **O'Brien CA**, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2007; **445**: 106-110 [PMID: 17122772 DOI: 10.1038/nature05372]

52 **Barker N**, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007; **449**: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]

53 **Takahashi H**, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, Doki Y, Mori M. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. *Ann Surg Oncol* 2011; **18**: 1166-1174 [PMID: 21125339 DOI: 10.1245/s10434-010-1373-9]

54 **Shimokawa M**, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, Date S, Sugimoto S, Kanai T, Sato T. Visualization and targeting of LGR5(+) human colon cancer stem cells. *Nature* 2017; **545**: 187-192 [PMID: 28355176 DOI: 10.1038/nature22081]

55 **de Sousa e Melo F**, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z, Koeppen H, Dijkgraaf GJ, Piskol R, de Sauvage FJ. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. *Nature* 2017; **543**: 676-680 [PMID: 28358093 DOI: 10.1038/nature21713]

56 **Leng Z**, Xia Q, Chen J, Li Y, Xu J, Zhao E, Zheng H, Ai W, Dong J. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer. *Cell Physiol Biochem* 2018; **46**: 860-872 [PMID: 29627827 DOI: 10.1159/000488743]

57 **Kemper K**, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. *Stem Cells* 2012; **30**: 2378-2386 [PMID: 22969042 DOI: 10.1002/stem.1233]

58 **AbdelMageed M**, Ismail HTH, Olsson L, Lindmark G, Hammarström ML, Hammarström S, Sitohy B. Clinical Significance of Stem Cell Biomarkers EpCAM, LGR5 and LGR4 mRNA Levels in Lymph Nodes of Colon Cancer Patients. *Int J Mol Sci* 2021; **23** [PMID: 35008827 DOI: 10.3390/ijms23010403]

59 **Lin CW**, Liao MY, Lin WW, Wang YP, Lu TY, Wu HC. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. *J Biol Chem* 2012; **287**: 39449-39459 [PMID: 22989882 DOI: 10.1074/jbc.M112.386235]

60 **Dalerba P**, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci U S A* 2007; **104**: 10158-10163 [PMID: 17548814 DOI: 10.1073/pnas.0703478104]

61 **Roy K**, Kanwar RK, Kanwar JR. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging. *Biomaterials* 2015; **71**: 84-99 [PMID: 26318819 DOI: 10.1016/j.biomaterials.2015.07.055]

62 **Liu D**, Sun J, Zhu J, Zhou H, Zhang X, Zhang Y. Expression and clinical significance of colorectal cancer stem cell marker EpCAM(high)/CD44(+) in colorectal cancer. *Oncol Lett* 2014; **7**: 1544-1548 [PMID: 24765173 DOI: 10.3892/ol.2014.1907]

63 **Du L**, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. *Clin Cancer Res* 2008; **14**: 6751-6760 [PMID: 18980968 DOI: 10.1158/1078-0432.CCR-08-1034]

64 **Kapeleris J**, Zou H, Qi Y, Gu Y, Li J, Schoning J, Monteiro MJ, Gu W. Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials. *Clin Exp Pharmacol Physiol* 2020; **47**: 838-847 [PMID: 31883392 DOI: 10.1111/1440-1681.13247]

65 **Jing F**, Kim HJ, Kim CH, Kim YJ, Lee JH, Kim HR. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. *Int J Oncol* 2015; **46**: 1582-1588 [PMID: 25625240 DOI: 10.3892/ijo.2015.2844]

66 **Huang EH**, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* 2009; **69**: 3382-3389 [PMID: 19336570 DOI: 10.1158/0008-5472.CAN-08-4418]

67 **Kozovska Z**, Patsalias A, Bajzik V, Durinikova E, Demkova L, Jargasova S, Smolkova B, Plava J, Kucerova L, Matuskova M. ALDH1A inhibition sensitizes colon cancer cells to chemotherapy. *BMC Cancer* 2018; **18**: 656 [PMID: 29902974 DOI: 10.1186/s12885-018-4572-6]

68 **Holah NS**, Aiad HA, Asaad NY, Elkhouly EA, Lasheen AG. Evaluation of the Role of ALDH1 as Cancer Stem Cell Marker in Colorectal Carcinoma: An Immunohistochemical Study. *J Clin Diagn Res* 2017; **11**: EC17-EC23 [PMID: 28273973 DOI: 10.7860/JCDR/2017/22671.9291]

69 **Wang J**, Zhang B, Wu H, Cai J, Sui X, Wang Y, Li H, Qiu Y, Wang T, Chen Z, Zhu Q, Xia H, Song W, Xiang AP. CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells. *Oncogene* 2017; **36**: 1351-1363 [PMID: 27593923 DOI: 10.1038/onc.2016.299]

70 **Wiener Z**, Högström J, Hyvönen V, Band AM, Kallio P, Holopainen T, Dufva O, Haglund C, Kruuna O, Oliver G, Ben-Neriah Y, Alitalo K. Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance. *Cell Rep* 2014; **8**: 1943-1956 [PMID: 25242330 DOI: 10.1016/j.celrep.2014.08.034]

71 **Abdelrahman AE**, El-Azony A, Elsebai E, Ibrahim HM. Prognostic Impact of LGR5, Prox1, and Notch1 Biomarkers in Stage II to III Colon Cancer. *Appl Immunohistochem Mol Morphol* 2022; **30**: 126-135 [PMID: 34657081 DOI: 10.1097/PAI.0000000000000983]

72 **Shafaei S**, Sharbatdaran M, Kamrani G, Khafri S. The association between CD166 detection rate and clinicopathologic parameters of patients with colorectal cancer. *Caspian J Intern Med* 2013; **4**: 768-772 [PMID: 24294471]

73 **Guo Q**, Grimmig T, Gonzalez G, Giobbie-Hurder A, Berg G, Carr N, Wilson BJ, Banerjee P, Ma J, Gold JS, Nandi B, Huang Q, Waaga-Gasser AM, Lian CG, Murphy GF, Frank MH, Gasser M, Frank NY. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. *J Biol Chem* 2018; **293**: 11166-11178 [PMID: 29789423 DOI: 10.1074/jbc.RA118.003187]

74 **Chan KS**, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. *Proc Natl Acad Sci U S A* 2009; **106**: 14016-14021 [PMID: 19666525 DOI: 10.1073/pnas.0906549106]

75 **Yang YM**, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. *Cancer Invest* 2008; **26**: 725-733 [PMID: 18608209 DOI: 10.1080/07357900801941845]

76 **van der Horst G**, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. *Mol Cancer Res* 2012; **10**: 995-1009 [PMID: 22714124 DOI: 10.1158/1541-7786.MCR-12-0274]

77 **Aghaalikhani N**, Rashtchizadeh N, Shadpour P, Allameh A, Mahmoodi M. Cancer stem cells as a therapeutic target in bladder cancer. *J Cell Physiol* 2019; **234**: 3197-3206 [PMID: 30471107 DOI: 10.1002/jcp.26916]

78 **Ferreira-Teixeira M**, Parada B, Rodrigues-Santos P, Alves V, Ramalho JS, Caramelo F, Sousa V, Reis F, Gomes CM. Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. *Oncotarget* 2015; **6**: 36185-36201 [PMID: 26452033 DOI: 10.18632/oncotarget.5517]

79 **Li Y**, Lin K, Yang Z, Han N, Quan X, Guo X, Li C. Bladder cancer stem cells: clonal origin and therapeutic perspectives. *Oncotarget* 2017; **8**: 66668-66679 [PMID: 29029546 DOI: 10.18632/oncotarget.19112]

80 **Tan J**, Wang Y, Sun L, Xu S, Li C, Jin X. The Origin and Evolution of Bladder Cancer Stem Cells. *Front Cell Dev Biol* 2022; **10**: 950241 [PMID: 35903544 DOI: 10.3389/fcell.2022.950241]

81 **Kong F**, Gao F, Li H, Liu H, Zhang Y, Zheng R, Zhang Y, Chen J, Li X, Liu G, Jia Y. CD47: a potential immunotherapy target for eliminating cancer cells. *Clin Transl Oncol* 2016; **18**: 1051-1055 [PMID: 26830085 DOI: 10.1007/s12094-016-1489-x]

82 **Falso MJ**, Buchholz BA, White RW. Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. *Anticancer Res* 2012; **32**: 733-738 [PMID: 22399585]

83 **Su Y**, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA, Jiang F. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 327-337 [PMID: 20142235 DOI: 10.1158/1055-9965.EPI-09-0865]

84 **Brandt WD**, Matsui W, Rosenberg JE, He X, Ling S, Schaeffer EM, Berman DM. Urothelial carcinoma: stem cells on the edge. *Cancer Metastasis Rev* 2009; **28**: 291-304 [PMID: 20012172 DOI: 10.1007/s10555-009-9187-6]

85 **He X**, Marchionni L, Hansel DE, Yu W, Sood A, Yang J, Parmigiani G, Matsui W, Berman DM. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. *Stem Cells* 2009; **27**: 1487-1495 [PMID: 19544456 DOI: 10.1002/stem.92]

86 **Hatina J**, Schulz WA. Stem cells in the biology of normal urothelium and urothelial carcinoma. *Neoplasma* 2012; **59**: 728-736 [PMID: 22862174 DOI: 10.4149/neo\_2012\_089]

87 **Huang P**, Watanabe M, Kaku H, Ueki H, Noguchi H, Sugimoto M, Hirata T, Yamada H, Takei K, Zheng S, Xu K, Nasu Y, Fujii Y, Liu C, Kumon H. Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line. *Mol Clin Oncol* 2013; **1**: 180-184 [PMID: 24649144 DOI: 10.3892/mco.2012.29]

88 **Yin B**, Zeng Y, Liu G, Wang X, Wang P, Song Y. MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells. *Int J Clin Exp Pathol* 2014; **7**: 2934-2941 [PMID: 25031712]

89 **Xia P**, Liu DH, Xu ZJ, Ren F. Cancer Stem Cell Markers for Urinary Carcinoma. *Stem Cells Int* 2022; **2022**: 3611677 [PMID: 35342431 DOI: 10.1155/2022/3611677]

90 **Al-Hajj M**, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003; **100**: 3983-3988 [PMID: 12629218 DOI: 10.1073/pnas.0530291100]

91 **DA Cruz Paula A**, Lopes C. Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer. *Anticancer Res* 2017; **37**: 2173-2183 [PMID: 28476780 DOI: 10.21873/anticanres.11552]

92 **Miletti-González KE**, Murphy K, Kumaran MN, Ravindranath AK, Wernyj RP, Kaur S, Miles GD, Lim E, Chan R, Chekmareva M, Heller DS, Foran D, Chen W, Reiss M, Bandera EV, Scotto K, Rodríguez-Rodríguez L. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. *J Biol Chem* 2012; **287**: 18995-19007 [PMID: 22433859 DOI: 10.1074/jbc.M111.318774]

93 **Cho Y**, Lee HW, Kang HG, Kim HY, Kim SJ, Chun KH. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. *Oncotarget* 2015; **6**: 8709-8721 [PMID: 25909162 DOI: 10.18632/oncotarget.3325]

94 **Fang X**, Zheng P, Tang J, Liu Y. CD24: from A to Z. *Cell Mol Immunol* 2010; **7**: 100-103 [PMID: 20154703 DOI: 10.1038/cmi.2009.119]

95 **Jaggupilli A**, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. *Clin Dev Immunol* 2012; **2012**: 708036 [PMID: 22693526 DOI: 10.1155/2012/708036]

96 **Ginestier C**, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 2007; **1**: 555-567 [PMID: 18371393 DOI: 10.1016/j.stem.2007.08.014]

97 **Ginestier C**, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS, Birnbaum D, Charafe-Jauffret E. Retinoid signaling regulates breast cancer stem cell differentiation. *Cell Cycle* 2009; **8**: 3297-3302 [PMID: 19806016 DOI: 10.4161/cc.8.20.9761]

98 **Li W**, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. *Sci Rep* 2017; **7**: 13856 [PMID: 29062075 DOI: 10.1038/s41598-017-14364-2]

99 **Zhang X**, Powell K, Li L. Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond. *Cancers (Basel)* 2020; **12** [PMID: 33327542 DOI: 10.3390/cancers12123765]

100 **Butti R**, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC. Breast cancer stem cells: Biology and therapeutic implications. *Int J Biochem Cell Biol* 2019; **107**: 38-52 [PMID: 30529656 DOI: 10.1016/j.biocel.2018.12.001]

101 **Ali HR**, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. *Breast Cancer Res* 2011; **13**: R118 [PMID: 22112299 DOI: 10.1186/bcr3061]

102 **Testa U**, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. *Cancers (Basel)* 2018; **10** [PMID: 30060526 DOI: 10.3390/cancers10080248]

103 **Ferragut F**, Vachetta VS, Troncoso MF, Rabinovich GA, Elola MT. ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression. *Cytokine Growth Factor Rev* 2021; **61**: 27-37 [PMID: 34272152 DOI: 10.1016/j.cytogfr.2021.07.001]

104 **Zhang WC**, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, Bhakoo KK, Jayapal SR, Nichane M, Yu Q, Ahmed DA, Tan C, Sing WP, Tam J, Thirugananam A, Noghabi MS, Pang YH, Ang HS, Mitchell W, Robson P, Kaldis P, Soo RA, Swarup S, Lim EH, Lim B. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. *Cell* 2012; **148**: 259-272 [PMID: 22225612 DOI: 10.1016/j.cell.2011.11.050]

105 **Zhang DG**, Jiang AG, Lu HY, Zhang LX, Gao XY. Isolation, cultivation and identification of human lung adenocarcinoma stem cells. *Oncol Lett* 2015; **9**: 47-54 [PMID: 25435932 DOI: 10.3892/ol.2014.2639]

106 **Eramo A**, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ* 2008; **15**: 504-514 [PMID: 18049477 DOI: 10.1038/sj.cdd.4402283]

107 **Wang S**, Xu ZY, Wang LF, Su W. CD133+ cancer stem cells in lung cancer. *Front Biosci (Landmark Ed)* 2013; **18**: 447-453 [PMID: 23276935 DOI: 10.2741/4113]

108 **Leung EL**, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. *PLoS One* 2010; **5**: e14062 [PMID: 21124918 DOI: 10.1371/journal.pone.0014062]

109 **Sauzay C**, Voutetakis K, Chatziioannou A, Chevet E, Avril T. CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule. *Front Cell Dev Biol* 2019; **7**: 66 [PMID: 31080802 DOI: 10.3389/fcell.2019.00066]

110 **Yan X**, Luo H, Zhou X, Zhu B, Wang Y, Bian X. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. *Oncol Rep* 2013; **30**: 2733-2740 [PMID: 24101104 DOI: 10.3892/or.2013.2784]

111 **Ucar D**, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. *Chem Biol Interact* 2009; **178**: 48-55 [PMID: 18952074 DOI: 10.1016/j.cbi.2008.09.029]

112 **Jiang F**, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. *Mol Cancer Res* 2009; **7**: 330-338 [PMID: 19276181 DOI: 10.1158/1541-7786.MCR-08-0393]

113 **Shao C**, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez-Canales J, Liu H, Behrens C, Shay JW, Wistuba II, Minna JD. Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. *Clin Cancer Res* 2014; **20**: 4154-4166 [PMID: 24907115 DOI: 10.1158/1078-0432.CCR-13-3292]

114 **Yu J**, Alharbi A, Shan H, Hao Y, Snetsinger B, Rauh MJ, Yang X. TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1. *Oncotarget* 2017; **8**: 38426-38443 [PMID: 28415606 DOI: 10.18632/oncotarget.16430]

115 **MacDonagh L**, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. *Oncotarget* 2017; **8**: 72544-72563 [PMID: 29069808 DOI: 10.18632/oncotarget.19881]

116 **Nimmakayala RK**, Batra SK, Ponnusamy MP. Unraveling the journey of cancer stem cells from origin to metastasis. *Biochim Biophys Acta Rev Cancer* 2019; **1871**: 50-63 [PMID: 30419314 DOI: 10.1016/j.bbcan.2018.10.006]

117 **Prince ME**, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc Natl Acad Sci U S A* 2007; **104**: 973-978 [PMID: 17210912 DOI: 10.1073/pnas.0610117104]

118 **Herreros-Pomares A**. Identification, Culture and Targeting of Cancer Stem Cells. *Life (Basel)* 2022; **12** [PMID: 35207472 DOI: 10.3390/life12020184]

119 **Dragu DL**, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: Current trends and future challenges. *World J Stem Cells* 2015; **7**: 1185-1201 [PMID: 26516409 DOI: 10.4252/wjsc.v7.i9.1185]

120 **Hait WN**. Anticancer drug development: the grand challenges. *Nat Rev Drug Discov* 2010; **9**: 253-254 [PMID: 20369394 DOI: 10.1038/nrd3144]

121 **Shultz LD**, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. *Nat Rev Immunol* 2012; **12**: 786-798 [PMID: 23059428 DOI: 10.1038/nri3311]

122 **Plaks V**, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell* 2015; **16**: 225-238 [PMID: 25748930 DOI: 10.1016/j.stem.2015.02.015]

123 **Miserocchi G**, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. *J Transl Med* 2017; **15**: 229 [PMID: 29116016 DOI: 10.1186/s12967-017-1328-z]

124 **Dzobo K**, Rowe A, Senthebane DA, AlMazyadi MAM, Patten V, Parker MI. Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling. *OMICS* 2018; **22**: 733-748 [PMID: 30571609 DOI: 10.1089/omi.2018.0172]

125 **Lancaster MA**, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science* 2014; **345**: 1247125 [PMID: 25035496 DOI: 10.1126/science.1247125]

126 **Sato T**, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus structures *in vitro* without a mesenchymal niche. *Nature* 2009; **459**: 262-265 [PMID: 19329995 DOI: 10.1038/nature07935]

127 **Sato T**, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 2011; **141**: 1762-1772 [PMID: 21889923 DOI: 10.1053/j.gastro.2011.07.050]

128 **Takasato M**, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, Wolvetang EJ, Roost MS, Chuva de Sousa Lopes SM, Little MH. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. *Nature* 2015; **526**: 564-568 [PMID: 26444236 DOI: 10.1038/nature15695]

129 **Broutier L**, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, Huch M. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. *Nat Protoc* 2016; **11**: 1724-1743 [PMID: 27560176 DOI: 10.1038/nprot.2016.097]

130 **Hoang P**, Wang J, Conklin BR, Healy KE, Ma Z. Generation of spatial-patterned early-developing cardiac organoids using human pluripotent stem cells. *Nat Protoc* 2018; **13**: 723-737 [PMID: 29543795 DOI: 10.1038/nprot.2018.006]

131 **Wong AP**, Bear CE, Chin S, Pasceri P, Thompson TO, Huan LJ, Ratjen F, Ellis J, Rossant J. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. *Nat Biotechnol* 2012; **30**: 876-882 [PMID: 22922672 DOI: 10.1038/nbt.2328]

132 **Gao D**, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y. Organoid cultures derived from patients with advanced prostate cancer. *Cell* 2014; **159**: 176-187 [PMID: 25201530 DOI: 10.1016/j.cell.2014.08.016]

133 **Kim M**, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, Choi EK, Jeong SY, Taylor AM, Jain S, Meyerson M, Jang SJ. Patient-derived lung cancer organoids as *in vitro* cancer models for therapeutic screening. *Nat Commun* 2019; **10**: 3991 [PMID: 31488816 DOI: 10.1038/s41467-019-11867-6]

134 **Sachs N**, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, Korving J, van Boxtel R, Duarte AA, Lelieveld D, van Hoeck A, Ernst RF, Blokzijl F, Nijman IJ, Hoogstraat M, van de Ven M, Egan DA, Zinzalla V, Moll J, Boj SF, Voest EE, Wessels L, van Diest PJ, Rottenberg S, Vries RGJ, Cuppen E, Clevers H. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. *Cell* 2018; **172**: 373-386.e10 [PMID: 29224780 DOI: 10.1016/j.cell.2017.11.010]

135 **Abugomaa A,** Elbadawy M. Patient-derived organoid analysis of drug resistance in precision medicine: is there a value? In: Expert Review of Precision Medicine and Drug Developmen. London: Taylor & Francis; 2020, pp. 1-5 [DOI:10.1080/23808993.2020.1715794]

136 **Shamir ER**, Ewald AJ. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. *Nat Rev Mol Cell Biol* 2014; **15**: 647-664 [PMID: 25237826 DOI: 10.1038/nrm3873]

137 **Pauli C**, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA. Personalized *In Vitro* and *In Vivo* Cancer Models to Guide Precision Medicine. *Cancer Discov* 2017; **7**: 462-477 [PMID: 28331002 DOI: 10.1158/2159-8290.CD-16-1154]

138 **Porter RJ**, Murray GI, McLean MH. Current concepts in tumour-derived organoids. *Br J Cancer* 2020; **123**: 1209-1218 [PMID: 32728094 DOI: 10.1038/s41416-020-0993-5]

139 **Fatehullah A**, Tan SH, Barker N. Organoids as an *in vitro* model of human development and disease. *Nat Cell Biol* 2016; **18**: 246-254 [PMID: 26911908 DOI: 10.1038/ncb3312]

140 **Driehuis E**, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. *Nat Protoc* 2020; **15**: 3380-3409 [PMID: 32929210 DOI: 10.1038/s41596-020-0379-4]

141 **Elbadawy M**, Sato Y, Mori T, Goto Y, Hayashi K, Yamanaka M, Azakami D, Uchide T, Fukushima R, Yoshida T, Shibutani M, Kobayashi M, Shinohara Y, Abugomaa A, Kaneda M, Yamawaki H, Usui T, Sasaki K. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. *Cancer Biol Ther* 2021; **22**: 357-371 [PMID: 34034619 DOI: 10.1080/15384047.2021.1919004]

142 **Xu H**, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. *J Hematol Oncol* 2018; **11**: 116 [PMID: 30219074 DOI: 10.1186/s13045-018-0662-9]

143 **Rossi G**, Manfrin A, Lutolf MP. Progress and potential in organoid research. *Nat Rev Genet* 2018; **19**: 671-687 [PMID: 30228295 DOI: 10.1038/s41576-018-0051-9]

144 **Liu L**, Yu L, Li Z, Li W, Huang W. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. *J Transl Med* 2021; **19**: 40 [PMID: 33478472 DOI: 10.1186/s12967-020-02677-2]

145 **Orkin RW**, Gehron P, McGoodwin EB, Martin GR, Valentine T, Swarm R. A murine tumor producing a matrix of basement membrane. *J Exp Med* 1977; **145**: 204-220 [PMID: 830788 DOI: 10.1084/jem.145.1.204]

146 **Kleinman HK**, Martin GR. Matrigel: basement membrane matrix with biological activity. *Semin Cancer Biol* 2005; **15**: 378-386 [PMID: 15975825 DOI: 10.1016/j.semcancer.2005.05.004]

147 **Lee HJ**, Mun S, Pham DM, Kim P. Extracellular Matrix-Based Hydrogels to Tailoring Tumor Organoids. *ACS Biomater Sci Eng* 2021; **7**: 4128-4135 [PMID: 33724792 DOI: 10.1021/acsbiomaterials.0c01801]

148 **Benton G**, Arnaoutova I, George J, Kleinman HK, Koblinski J. Matrigel: from discovery and ECM mimicry to assays and models for cancer research. *Adv Drug Deliv Rev* 2014; **79-80**: 3-18 [PMID: 24997339 DOI: 10.1016/j.addr.2014.06.005]

149 **Drost J**, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, Clevers H. Organoid culture systems for prostate epithelial and cancer tissue. *Nat Protoc* 2016; **11**: 347-358 [PMID: 26797458 DOI: 10.1038/nprot.2016.006]

150 **Cheaito K**, Bahmad HF, Hadadeh O, Msheik H, Monzer A, Ballout F, Dagher C, Telvizian T, Saheb N, Tawil A, El-Sabban M, El-Hajj A, Mukherji D, Al-Sayegh M, Abou-Kheir W. Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer. *Oncol Lett* 2022; **23**: 6 [PMID: 34820005 DOI: 10.3892/ol.2021.13124]

151 **Monzer A**, Wakimian K, Ballout F, Al Bitar S, Yehya A, Kanso M, Saheb N, Tawil A, Doughan S, Hussein M, Mukherji D, Faraj W, Gali-Muhtasib H, Abou-Kheir W. Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional *in vitro* models. *World J Gastroenterol* 2022; **28**: 4787-4811 [PMID: 36156922 DOI: 10.3748/wjg.v28.i33.4787]

152 **Al Bitar S**, Ballout F, Monzer A, Kanso M, Saheb N, Mukherji D, Faraj W, Tawil A, Doughan S, Hussein M, Abou-Kheir W, Gali-Muhtasib H. Thymoquinone Radiosensitizes Human Colorectal Cancer Cells in 2D and 3D Culture Models. *Cancers (Basel)* 2022; **14** [PMID: 35326517 DOI: 10.3390/cancers14061363]

153 **Yu L**, Li Z, Mei H, Li W, Chen D, Liu L, Zhang Z, Sun Y, Song F, Chen W, Huang W. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells *in vitro*. *Clin Transl Immunology* 2021; **10**: e1248 [PMID: 33552510 DOI: 10.1002/cti2.1248]

154 **Chen P**, Zhang X, Ding R, Yang L, Lyu X, Zeng J, Lei JH, Wang L, Bi J, Shao N, Shu D, Wu B, Wu J, Yang Z, Wang H, Wang B, Xiong K, Lu Y, Fu S, Choi TK, Lon NW, Zhang A, Tang D, Quan Y, Meng Y, Miao K, Sun H, Zhao M, Bao J, Zhang L, Xu X, Shi Y, Lin Y, Deng C. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer. *Adv Sci (Weinh)* 2021; **8**: e2101176 [PMID: 34605222 DOI: 10.1002/advs.202101176]

155 **Cheaito K**, Bahmad HF, Jalloul H, Hadadeh O, Msheik H, El-Hajj A, Mukherji D, Al-Sayegh M, Abou-Kheir W. Epidermal Growth Factor Is Essential for the Maintenance of Novel Prostate Epithelial Cells Isolated From Patient-Derived Organoids. *Front Cell Dev Biol* 2020; **8**: 571677 [PMID: 33195205 DOI: 10.3389/fcell.2020.571677]

156 **Huang Y**, Huang Z, Tang Z, Chen Y, Huang M, Liu H, Huang W, Ye Q, Jia B. Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models. *Front Cell Dev Biol* 2021; **9**: 740574 [PMID: 34869324 DOI: 10.3389/fcell.2021.740574]

157 **Bose S**, Clevers H, Shen X. Promises and Challenges of Organoid-Guided Precision Medicine. *Med* 2021; **2**: 1011-1026 [PMID: 34617071 DOI: 10.1016/j.medj.2021.08.005]

158 **Foo MA**, You M, Chan SL, Sethi G, Bonney GK, Yong WP, Chow EK, Fong ELS, Wang L, Goh BC. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. *Biomark Res* 2022; **10**: 10 [PMID: 35272694 DOI: 10.1186/s40364-022-00356-6]

159 **Hurt EM**, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. *Br J Cancer* 2008; **98**: 756-765 [PMID: 18268494 DOI: 10.1038/sj.bjc.6604242]

160 **Ooki A**, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO. CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. *Br J Cancer* 2018; **119**: 961-970 [PMID: 30327565 DOI: 10.1038/s41416-018-0291-7]

161 **Vázquez-Iglesias L**, Barcia-Castro L, Rodríguez-Quiroga M, Páez de la Cadena M, Rodríguez-Berrocal J, Cordero OJ. Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26(+) cancer stem cells subsets. *Biol Open* 2019; **8** [PMID: 31285270 DOI: 10.1242/bio.041673]

162 **El-Benhawy SA**, Morsi MI, Fahmy EI, Soula MA, Khalil FAZF, Arab AR. Role of Resveratrol as Radiosensitizer by Targeting Cancer Stem Cells in Radioresistant Prostate Cancer Cells (PC-3). *Asian Pac J Cancer Prev* 2021; **22**: 3823-3837 [PMID: 34967561 DOI: 10.31557/APJCP.2021.22.12.3823]

163 **Zou J**, Yu XF, Bao ZJ, Dong J. Proteome of human colon cancer stem cells: a comparative analysis. *World J Gastroenterol* 2011; **17**: 1276-1285 [PMID: 21455326 DOI: 10.3748/wjg.v17.i10.1276]

164 **Gardelli C**, Russo L, Cipolla L, Moro M, Andriani F, Rondinone O, Nicotra F, Sozzi G, Bertolini G, Roz L. Differential glycosylation of collagen modulates lung cancer stem cell subsets through β1 integrin-mediated interactions. *Cancer Sci* 2021; **112**: 217-230 [PMID: 33068069 DOI: 10.1111/cas.14700]

165 **Senbanjo LT**, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. *Front Cell Dev Biol* 2017; **5**: 18 [PMID: 28326306 DOI: 10.3389/fcell.2017.00018]

166 **Tan W**, Tang H, Jiang X, Ye F, Huang L, Shi D, Li L, Huang X, Li L, Xie X, Xie X. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47. *J Cell Mol Med* 2019; **23**: 5994-6004 [PMID: 31273952 DOI: 10.1111/jcmm.14462]

167 **Liu L**, Zhang L, Yang L, Li H, Li R, Yu J, Yang L, Wei F, Yan C, Sun Q, Zhao H, Yang F, Jin H, Wang J, Wang SE, Ren X. Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. *Front Immunol* 2017; **8**: 404 [PMID: 28484448 DOI: 10.3389/fimmu.2017.00404]

168 **Hoogland AM**, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease. *Prostate* 2014; **74**: 488-496 [PMID: 24375374 DOI: 10.1002/pros.22768]

169 **Botchkina IL**, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. *Cancer Genomics Proteomics* 2009; **6**: 19-29 [PMID: 19451087]

170 **Martin TA**, Jiang WG. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. *Oncol Rep* 2014; **31**: 262-272 [PMID: 24173498 DOI: 10.3892/or.2013.2813]

171 **Wang P**, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NA, Kvalheim G, Gaudernack G. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. *PLoS One* 2013; **8**: e57020 [PMID: 23469181 DOI: 10.1371/journal.pone.0057020]

172 **Marcinkiewicz K**, Scotland KB, Boorjian SA, Nilsson EM, Persson JL, Abrahamsson PA, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP. The androgen receptor and stem cell pathways in prostate and bladder cancers (review). *Int J Oncol* 2012; **40**: 5-12 [PMID: 21956088 DOI: 10.3892/ijo.2011.1212]

173 **Zhang Y**, Xu W, Guo H, Zhang Y, He Y, Lee SH, Song X, Li X, Guo Y, Zhao Y, Ding C, Ning F, Ma Y, Lei QY, Hu X, Li S, Guo W. NOTCH1 Signaling Regulates Self-Renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-Small Cell Lung Cancer. *Cancer Res* 2017; **77**: 3082-3091 [PMID: 28416482 DOI: 10.1158/0008-5472.CAN-16-1633]

174 **Sui X**, Cai J, Li H, He C, Zhou C, Dong Y, Chen L, Zhang B, Wang Y, Zhang Y, Qiu Y, Zhang Y, Zhao Y, Huang Y, Shen Y, Wu H, Xiao J, Mason C, Zhu Q, Han S. p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer. *Cell Death Dis* 2018; **9**: 523 [PMID: 29743605 DOI: 10.1038/s41419-018-0541-x]

175 **Gemei M**, Mirabelli P, Di Noto R, Corbo C, Iaccarino A, Zamboli A, Troncone G, Galizia G, Lieto E, Del Vecchio L, Salvatore F. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth *in vivo*. *Cancer* 2013; **119**: 729-738 [PMID: 23027178 DOI: 10.1002/cncr.27794]

176 **Dzobo K**, Ganz C, Thomford NE, Senthebane DA. Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development. *OMICS* 2021; **25**: 81-92 [PMID: 33170084 DOI: 10.1089/omi.2020.0185]

177 **Abugomaa A**, Elbadawy M, Yamawaki H, Usui T, Sasaki K. Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer. *Cells* 2020; **9** [PMID: 31963556 DOI: 10.3390/cells9010235]

178 **Foster BM**, Zaidi D, Young TR, Mobley ME, Kerr BA. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. *Biomedicines* 2018; **6** [PMID: 29518044 DOI: 10.3390/biomedicines6010031]

179 **Ying J**, Tsujii M, Kondo J, Hayashi Y, Kato M, Akasaka T, Inoue T, Shiraishi E, Inoue T, Hiyama S, Tsujii Y, Maekawa A, Kawai S, Fujinaga T, Araki M, Shinzaki S, Watabe K, Nishida T, Iijima H, Takehara T. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells. *Int J Oncol* 2015; **46**: 1551-1559 [PMID: 25625841 DOI: 10.3892/ijo.2015.2851]

180 **Sorrentino C**, Ciummo SL, D'Antonio L, Fieni C, Lanuti P, Turdo A, Todaro M, Di Carlo E. Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome. *J Immunother Cancer* 2021; **9** [PMID: 34663639 DOI: 10.1136/jitc-2021-002966]

181 **Zhang S**, Yang X, Wang L, Zhang C. Interplay between inflammatory tumor microenvironment and cancer stem cells. *Oncol Lett* 2018; **16**: 679-686 [PMID: 29963133 DOI: 10.3892/ol.2018.8716]

182 **Mărgaritescu C**, Pirici D, Cherciu I, Bărbălan A, Cârtână T, Săftoiu A. CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma. *J Gastrointestin Liver Dis* 2014; **23**: 161-170 [PMID: 24949608]

183 **Gao X**, Dong QZ. Advance in metabolism and target therapy in breast cancer stem cells. *World J Stem Cells* 2020; **12**: 1295-1306 [PMID: 33312399 DOI: 10.4252/wjsc.v12.i11.1295]

184 **Bryan RT**. Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. *Philos Trans R Soc Lond B Biol Sci* 2015; **370**: 20140042 [PMID: 25533099 DOI: 10.1098/rstb.2014.0042]

185 **Wang R**, Yang L, Li S, Ye D, Yang L, Liu Q, Zhao Z, Cai Q, Tan J, Li X. Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM). *Med Sci Monit* 2018; **24**: 412-420 [PMID: 29353288 DOI: 10.12659/MSM.908022]

186 **Kirkland SC**. Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. *Br J Cancer* 2009; **101**: 320-326 [PMID: 19568234 DOI: 10.1038/sj.bjc.6605143]

187 **Hirashima K**, Yue F, Kobayashi M, Uchida Y, Nakamura S, Tomotsune D, Matsumoto K, Takizawa-Shirasawa S, Yokoyama T, Kanno H, Sasaki K. Cell biological profiling of reprogrammed cancer stem cell-like colon cancer cells maintained in culture. *Cell Tissue Res* 2019; **375**: 697-707 [PMID: 30284085 DOI: 10.1007/s00441-018-2933-8]

188 **Serna N**, Álamo P, Ramesh P, Vinokurova D, Sánchez-García L, Unzueta U, Gallardo A, Céspedes MV, Vázquez E, Villaverde A, Mangues R, Medema JP. Nanostructured toxins for the selective destruction of drug-resistant human CXCR4(+) colorectal cancer stem cells. *J Control Release* 2020; **320**: 96-104 [PMID: 31931052 DOI: 10.1016/j.jconrel.2020.01.019]

189 **Yi T**, Zhai B, Yu Y, Kiyotsugu Y, Raschle T, Etzkorn M, Seo HC, Nagiec M, Luna RE, Reinherz EL, Blenis J, Gygi SP, Wagner G. Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. *Proc Natl Acad Sci U S A* 2014; **111**: E2182-E2190 [PMID: 24782546 DOI: 10.1073/pnas.1404943111]

190 **Xie ZY**, Lv K, Xiong Y, Guo WH. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer. *Oncol Res Treat* 2014; **37**: 666-668, 670-672 [PMID: 25427584 DOI: 10.1159/000368842]

191 **Das S**, Mukherjee P, Chatterjee R, Jamal Z, Chatterji U. Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles. *Mol Cancer Ther* 2019; **18**: 680-692 [PMID: 30587555 DOI: 10.1158/1535-7163.MCT-18-0409]

192 **Green R**, Howell M, Khalil R, Nair R, Yan J, Foran E, Katiri S, Banerjee J, Singh M, Bharadwaj S, Mohapatra SS, Mohapatra S. Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway. *Sci Rep* 2019; **9**: 18177 [PMID: 31796785 DOI: 10.1038/s41598-019-54266-z]

193 **Lin CJ**, Yun EJ, Lo UG, Tai YL, Deng S, Hernandez E, Dang A, Chen YA, Saha D, Mu P, Lin H, Li TK, Shen TL, Lai CH, Hsieh JT. The paracrine induction of prostate cancer progression by caveolin-1. *Cell Death Dis* 2019; **10**: 834 [PMID: 31685812 DOI: 10.1038/s41419-019-2066-3]

194 **Wong N**, Major P, Kapoor A, Wei F, Yan J, Aziz T, Zheng M, Jayasekera D, Cutz JC, Chow MJ, Tang D. Amplification of MUC1 in prostate cancer metastasis and CRPC development. *Oncotarget* 2016; **7**: 83115-83133 [PMID: 27825118 DOI: 10.18632/oncotarget.13073]

195 **Guo M**, Luo B, Pan M, Li M, Zhao F, Dou J. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine. *Int Immunopharmacol* 2020; **85**: 106631 [PMID: 32470879 DOI: 10.1016/j.intimp.2020.106631]

196 **Bae KM**, Parker NN, Dai Y, Vieweg J, Siemann DW. E-cadherin plasticity in prostate cancer stem cell invasion. *Am J Cancer Res* 2011; **1**: 71-84 [PMID: 21968440]

197 **Tamura S**, Isobe T, Ariyama H, Nakano M, Kikushige Y, Takaishi S, Kusaba H, Takenaka K, Ueki T, Nakamura M, Akashi K, Baba E. E‑cadherin regulates proliferation of colorectal cancer stem cells through NANOG. *Oncol Rep* 2018; **40**: 693-703 [PMID: 29845283 DOI: 10.3892/or.2018.6464]

198 **Yun EJ**, Baek ST, Xie D, Tseng SF, Dobin T, Hernandez E, Zhou J, Zhang L, Yang J, Sun H, Xiao G, He D, Kittler R, Hsieh JT. DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. *Oncogene* 2015; **34**: 2741-2752 [PMID: 25043300 DOI: 10.1038/onc.2014.215]

199 **Yuan W**, Ji J, Shu Y, Chen J, Liu S, Wu L, Zhou Z, Liu Z, Tang Q, Zhang X, Shu X. Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer. *J Mol Med (Berl)* 2019; **97**: 89-102 [PMID: 30460377 DOI: 10.1007/s00109-018-1716-8]

200 **Preca BT**, Bajdak K, Mock K, Sundararajan V, Pfannstiel J, Maurer J, Wellner U, Hopt UT, Brummer T, Brabletz S, Brabletz T, Stemmler MP. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. *Int J Cancer* 2015; **137**: 2566-2577 [PMID: 26077342 DOI: 10.1002/ijc.29642]

201 **Qin J**, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. *Cell Stem Cell* 2012; **10**: 556-569 [PMID: 22560078 DOI: 10.1016/j.stem.2012.03.009]

202 **Garraway IP**, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration *in vivo*. *Prostate* 2010; **70**: 491-501 [PMID: 19938015 DOI: 10.1002/pros.21083]

203 **Chan KS**, Volkmer JP, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. *Curr Opin Urol* 2010; **20**: 393-397 [PMID: 20657288 DOI: 10.1097/MOU.0b013e32833cc9df]

204 **Ricardo S**, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. *J Clin Pathol* 2011; **64**: 937-946 [PMID: 21680574 DOI: 10.1136/jcp.2011.090456]

205 **Chen X**, Rycaj K, Liu X, Tang DG. New insights into prostate cancer stem cells. *Cell Cycle* 2013; **12**: 579-586 [PMID: 23370446 DOI: 10.4161/cc.23721]

206 **Shi R**, Liu L, Wang F, He Y, Niu Y, Wang C, Zhang X, Zhang X, Zhang H, Chen M, Wang Y. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer. *Cell Signal* 2020; **76**: 109810 [PMID: 33069797 DOI: 10.1016/j.cellsig.2020.109810]

207 **Chen Y**, Lan T. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer. *Urol Int* 2021; **105**: 337-353 [PMID: 32957106 DOI: 10.1159/000510124]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 28, 2022

**First decision:** January 31, 2023

**Article in press:**

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** Lebanon

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Crocé LS, Italy; Elbadawy M, Egypt **S-Editor:** Li L **L-Editor:** A **P-Editor:**

**Figure Legends**

图示

描述已自动生成

**Figure 1 Schematic presentation of cancer stem cell markers and their contribution to cancer development, progression, and resistance to therapy.** Several cancer stem cell (CSC) markers and regulatory signaling pathways are involved in the sustenance and activation of self-renewal, immune evasion, and tumor metastasis, and contribution to tumor re-growth and therapy resistance. CSC markers serve as potential therapeutic targets for cancer treatment. CSCs: Cancer stem cells.

图示

描述已自动生成

**Figure 2 Schematic presentation of patient-derived organoid applications in cancer research.** Patient-derived organoid (PDO) models can be utilized in multiple fields of cancer research including fundamental research, drug development, and clinical application. Cancer PDOs have been used to simulate the tumor tissue *in vitro*, study the disease mechanisms and gene expression patterns, and expose them to different drugs for efficacy screenings and drug discovery validations. Organoids are further used as *in vitro* pre-clinical models for personalized medicine and the generation of ‘living’ organoid biobanks. PDO culturing system serves as an advanced tool in the implementation and development of precision medicine.

**Table 1** **Summary of the most prominent biomarkers required to identify and isolate the tissue-specific cancer stem cells in prostate, colon, bladder, breast, and lung tumors**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| TSCSCs markers | PCSCs | CCSCs | BCSCs | BrCSCs | LCSCs | Ref. |
| CD24 | - | + | + | - |  | [64,90,159,160] |
| CD26 |  | + |  |  |  | [161] |
| CD29 | + | + |  | + | + | [99,162-164] |
| CD44 | + | + | + | + | + | [31,63,74,108,165] |
| CD47 |  |  | + | + | + | [78,166,167] |
| CD49b (integrin α2 or ITGA2) | + | + | - | + | + | [168-171] |
| CD49f (integrin α6 or ITGA6 | + | + | + | + | + | [99,169,172,173] |
| CD51 | + | + |  |  |  | [69,174] |
| CD61 |  |  |  | + |  | [99] |
| CD66c |  | + | - |  |  | [84,175] |
| CD67LR |  |  | + |  |  | [84] |
| CD87 |  |  |  |  | + | [116] |
| CD90 |  | + | + | + | + | [99,110,176,177] |
| CD117 | + |  |  | + | + | [38,116,178] |
| CD126 |  | + |  | + | + | [179-181] |
| CD133 | + | + | + | + | + | [28,51,87,99,107] |
| CD151 | + |  |  |  |  | [35] |
| CD166 | + | + |  | + | + | [46,104,182,183] |
| CD326 (EpCAM or ESA) | + | + | + | + | + | [48,56,116,184,185] |
| Integrin α2β1 | + | + |  |  |  | [27,186] |
| TRA-1-60 | + | + |  |  |  | [35,187] |
| Trop2 | + |  |  |  |  | [45] |
| CXCR4 | + | + |  | + | + | [102,162,188,189] |
| ABCB5 |  | + |  |  |  | [73] |
| ABCG2 | + | + | + | + | + | [49,102,177,190,191] |
| MAGE-A3 |  |  | + |  |  | [177] |
| GLDC |  |  |  |  | + | [102] |
| ALDH | + | + | + | + | + | [44,68,96,102,177] |
| BCMab1 |  |  | + |  |  | [79] |
| Lgr5 |  | + |  | + | + | [53,99,192] |
| Prox1 | + | + |  |  |  | [70,193] |
| EMA (MUC1) | + | + | - |  |  | [77,194,195] |
| E-cadherin | + | + |  |  |  | [196,197] |
| ZEB-1 | + | + |  | + | + | [198-200] |
| PSA | - |  |  |  |  | [201] |
| CK5 | + |  | + | + | + | [117,202-204] |
| CK17 |  |  | + |  |  | [89] |
| CK18 | - |  | - | - |  | [89,205,206] |
| CK20 |  |  | - |  |  | [89] |
| Ar-v7 | + |  |  |  |  | [207] |

+: Over-expressed; -: Under-expressed; Blank: Not found in the literature/controversial. TSCSCs: Tissue-specific cancer stem cells; PCSCs: Prostate cancer stem cells; CCSCs: Colon cancer stem cells; BCSCs: Bladder cancer stem cells; BrCSCs: Breast cancer stem cells; LCSCs: Lung cancer stem cells; EpCAM: Epithelial cell adhesion molecule; TRA-1-60: T cell receptor alpha locus; ALDH: Aldehyde dehydrogenase; EMA: Epithelial membrane antigen.